Skip to main content
OpenTrials
Completed

NCT Number: NCT02675257

Depression and Diabetes Control Trial

This randomised controlled trial evaluates a cognitive-behavioural intervention for diabetes patients with suboptimal glycaemic control and comorbid depressive symptoms and/or diabetes distress. The main outcome is the improvement of suboptimal glycaemic control (HbA1c). Secondary outcomes are effects on depressive symptoms, diabetes distress, self-care behaviour, diabetes acceptance and quality of life. The treatment group will be treated with a cognitive-behavioural group treatment comprising specific interventions to improve glycaemic control and reduce diabetes distress as well as depressive symptoms. The control group will receive treatment-as-usual. A total of 212 study participants will be included. A secondary study objective is to analyse associations of suboptimal glycaemic control, depressive symptoms and diabetes distress with inflammatory markers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Diabetes Center Mergentheim, Bad Mergentheim, Baden-Wurttemberg, Germany

Loading trial locations.

About this study

Suboptimal glycaemic control is an established risk factor for the development of serious long-term complications of diabetes. Moreover, it is associated with elevated risks of significant hyperglycaemic acute events such as hyperosmolar hyperglycemic state or diabetic ketoacidosis. Hence, patients with diabetes and persistent suboptimal glycaemic control are at higher risk of having a rather poor prognosis.

Besides physiological and medical factors, psychological problems have been found to predict suboptimal glycaemic control. A number of studies found depressive symptoms to be independently associated with hyperglycaemia. Others focussed on diabetes-specific affective problems - the so called diabetes distress - and suggested this factor to be of great importance. Finally, some studies found that depressive symptoms and diabetes distress may interact, with the coocurrence of these factors being associated with the highest risk or suboptimal glycaemic control. The results correspond to other findings suggesting that both depressive symptoms and diabetes distress are often associated with reduced diabetes self-care, which can explain the associations of those factors with hyperglycaemia.

On the other hand, suboptimal glycaemic control could also be an explanation for affective problems - either mediated by physiological mechanisms or psychological ones, e.g. dissatisfaction or guilt. Hence, it is valid to assume that the link between depressive symptoms and/or diabetes distress may be bidirectional - although evidence to support this assumption is missing.

Following this evidence and background, the investigators designed the a to analyse the relationships between suboptimal glycaemic control, depressive symptoms and diabetes distress in diabetes using a prospective study design. The study is a randomized trial in which a cognitive-behavioural group treatment is compared to a treatment-as-usual condition (standard diabetes education) regarding their efficacy in improving suboptimal glycaemic control. 212 diabetes patients with suboptimal glycaemic control (HbA1c value > 7.5%) and elevated depressive symptoms (Center for Epidemiologic Studies Depressions Scale score ≥ 16) and/or elevated diabetes distress (Problem Areas In Diabetes Scale score ≥ 40) will be randomly assigned to either the treatment group or treatment-as-usual. The primary outcome is the improvement of suboptimal glycaemic control (reduction of HbA1c) in the 12-month follow-up. As secondary outcomes positive baseline-to-follow up changes regarding depressive symptoms, diabetes distress, diabetes self-care behaviour, diabetes acceptance and quality of life are assessed.

A second study objective is to analyse cross-sectional and prospective associations of suboptimal glycaemic control, depressive symptoms and diabetes distress with serum levels of the following inflammatory markers: hsCRP, IL-6, IL-18, IL-1Ra, MCP-1 and Adiponectin. Potential effects of the treatment groups on these markers will also be examined.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 70
  • Diabetes mellitus type 1 or type 2
  • Diabetes duration ≥ 1 year
  • Suboptimal glycaemic control (HbA1c > 7,5%)
  • Elevated depressive symptoms (CES-D score ≥ 16) and/or elevated diabetes distress (PAID score ≥ 40)
  • Sufficient language skills
  • Written informed consent

Exclusion criteria

  • Severe major depressive disorder according to ICD-10
  • Current psychiatric and/or psychotherapeutic treatment
  • Current antidepressive medical treatment
  • Suicidal ideation
  • Acute mental disorder of the following type: schizophrenia or other psychotic disorder, bipolar disorder, severe eating disorder (anorexia nervosa, bulimia nervosa), substance use disorder
  • History of personality disorder
  • Severe somatic illnesses: dialysis-dependent nephropathy, acute cancer, severe heart disease (NYHA III - IV), severe neurologic illness (e. g. MS, dementia), severe autoimmune disease
  • Terminal illness
  • Bedriddenness
  • Guardianship

Treatment and study plan

Diabetes-related affective problems analysis

Behavioral

Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control

Goal setting towards improvement of glycaemic control

Behavioral

Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress

Diabetes-specific problem-solving therapy

Behavioral

Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress

Interventions to increase diabetes treatment motivation

Behavioral

Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems

Activation of personal and social resources

Behavioral

Activation of personal and social resources with a view to diabetes control and affective problems

Reduction of barriers to self-care/glycaemic control

Behavioral

Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control

Cognitive restructuring of diabetes-related problems

Behavioral

Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems

Goal definition regarding self-care/glycaemia/well-being

Behavioral

Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms

Health care and specific topics (e. g. blood pressure)

Behavioral

Education on health care and specific topics (e. g. blood pressure)

Healthy foods, cooking recommendations, recipes

Behavioral

Education on healthy and unhealthy foods, cooking and recipes

Sports, activities and exercise

Behavioral

Education on sports, activities and exercise

Foot care: exercises, care & control, injuries, neuropathy

Behavioral

Education on foot care: exercises, care and control, injuries, and diabetic neuropathy

Diabetes complications

Behavioral

Education on diabetes complications

Social aspects of living with diabetes

Behavioral

Education on social aspects of living with diabetes

Primary outcomes

  1. Improvement of glycaemic control as measured by the HbA1c

    Time frame: 12 months

    Mean difference between HbA1c values at baseline and at 12 month follow

Secondary outcomes

  1. Improvement of glycaemic control as measured by participants' blood glucose meter or glucose monitoring devices (data are extracted from tools using the diasend application)

    Time frame: 12 months

    Mean difference between average glucose test scores during an 8-week period before baseline and those during an 8-week period before 12 month follow

  2. Improvement of depressive symptoms as measured with the Center for Epidemiologic Studies Depression Scale (CES-D)

    Time frame: 12 months

    Mean difference between CES-D scores at baseline and at 12 month follow up

  3. Improvement of depressive symptoms as measured with the Patient Health Questionnaire Module for Depression (PHQ-9)

    Time frame: 12 months

    Mean difference between PHQ-9 scores at baseline and at 12 month follow up

  4. IImprovement of diabetes distress as measured with the Problem Areas in Diabetes Scale (PAID)

    Time frame: 12 months

    Mean difference between PAID scores at baseline and at 12 month follow

  5. IImprovement of diabetes distress as measured with the Diabetes Distress Scale (DDS)

    Time frame: 12 months

    Mean difference between DDS scores at baseline and at 12 month follow

  6. Improvement of self-care behaviour as measured with the Summary of Diabetes Self-Care Activities Measure (SDSCA)

    Time frame: 12 months

    Mean difference between SDSCA scores at baseline and at 12 month follow

  7. Improvement of self-care behaviour as measured with the Diabetes Self-Management Questionnaire (DSMQ)

    Time frame: 12 months

    Mean difference between DSMQ scores at baseline and at 12 month follow

  8. Improvement of diabetes acceptance as measured with the Diabetes Acceptance Scale (DAS)

    Time frame: 12 months

    Mean difference between DAS scores at baseline and at 12 month follow

  9. Improvement of quality of life as measured with the EuroQol Five-Dimensions Questionnaire (EQ-5D)

    Time frame: 12 months

    Mean difference between EQ-5D scores at baseline and at 12 month follow

  10. Improvement of quality of life as measured with the Short Form-36 Health Survey (SF-36)

    Time frame: 12 months

    Mean difference between SF-36 scores at baseline and at 12 month follow

Other outcomes

  1. Inflammatory Marker: hsCRP

    Time frame: 12 months

    Mean difference between hsCRP scores at baseline and at 12 month follow

  2. Inflammatory Marker: IL-6

    Time frame: 12 months

    Mean difference between IL-6 scores at baseline and at 12 month follow

  3. Inflammatory Marker: IL-18

    Time frame: 12 months

    Mean difference between IL-18 scores at baseline and at 12 month follow

  4. Inflammatory Marker: IL-1Ra

    Time frame: 12 months

    Mean difference between IL-1Ra scores at baseline and at 12 month follow

  5. Inflammatory Marker: MCP-1

    Time frame: 12 months

    Mean difference between MCP-1 scores at baseline and at 12 month follow

  6. Inflammatory Marker: Adiponectin

    Time frame: 12 months

    Mean difference between Adiponectin scores at baseline and at 12 month follow

Sponsors and collaborators

Lead sponsor

Forschungsinstitut der Diabetes Akademie Mergentheim

Other

Collaborators

  • German Center for Diabetes Research
  • German Diabetes Center
  • German Federal Ministry of Education and Research
  • Helmholtz Zentrum München

Registry information

Acronym: DDCT

Important dates

Study start
2015
Primary completion
2018
Study completion
2018
First posted
Feb 5, 2016
Registry last updated
Aug 28, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.